Swiss To Offer More Data Protection For New Indications, Orphans, Pediatric Drugs
This article was originally published in SRA
Executive Summary
The Swiss parliament has approved the revised Therapeutic Products Law, which now includes a new 10-year data exclusivity period for significant new indications, 15 years of data protection for drugs for rare diseases, and a new six-month supplementary protection certificate (SPC) for pediatric medicines1.